样式: 排序: IF: - GO 导出 标记为已读
-
A Case of the Non-Caseating Granuloma Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-24 Dia R. Waguespack
An abstract is unavailable. This article is available as a PDF only.
-
Replacement Strategies for Tunneled Hemodialysis Catheters with Complications: A Nationwide Cohort Study Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-24 Benjamin Lazarus, Sradha Kotwal, Martin Gallagher, Nicholas A Gray, Sarah Coggan, Girish Talaulikar, Kevan R Polkinghorne, the REDUCCTION investigators (detailed in Supplemental Item 1)
lacement catheters inserted by either strategy. Methods: Observational data from the REDUCCTION trial, which enrolled a nationwide cohort of 6400 adults who received an incident hemodialysis catheter (2016-2020) was used for this secondary analysis. Tunneled catheters were replaced by either catheter exchange through the existing tunnel tract or removal and replacement through a new tract. The effect
-
Sleep Disorders and Dementia Risk in Older Patients with Kidney Failure: A Retrospective Cohort Study Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-24 Jane J. Long, Yusi Chen, Byoungjun Kim, Sunjae Bae, Yiting Li, Babak J. Orandi, Nadia M. Chu, Aarti Mathur, Dorry L. Segev, Mara A. McAdams-DeMarco
ith kidney failure (United States Renal Data System; 2008-2019), we estimated the risk of dementia (including subtypes) associated with sleep disorders using Cox proportional-hazard models with propensity score weighting. We tested whether positive airway pressure (PAP) therapy was associated with reduced dementia risk among patients with obstructive sleep apnea (OSA). Results: 26.3% of patients were
-
Twice Weekly Versus Thrice Weekly Hemodialysis – A Pilot Cross-Over Equivalence Trial Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-26 Seolhyun Lee, Nhat M. Pham, Maria E. Montez-Rath, Christian G. Bolanos, Saniya S. Bonde, Timothy W. Meyer, Tammy L. Sirich
hemodialysis according to this guideline on patients’ quality of life or uremic solute levels. Methods: Twenty six hemodialysis patients with average residual urea clearance (Kru) 4.7±1.8 ml/min and hemodialysis vintage of 12±15 months (range two months to 4.9 years) underwent a cross-over trial comparing four weeks of twice weekly hemodialysis and four weeks of thrice weekly hemodialysis. Twice weekly
-
Infection-Related Glomerulonephritis with Cutaneous Vasculitis Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-26 Jodi Gedallovich, Ralph M. Mohty, Ksenia Kasimova, Zhengchun Lu, Vivek Charu, John P. Higgins JP, Neeraja Kambham, Vanderlene L. Kung, Megan L. Troxell
An abstract is unavailable. This article is available as a PDF only.
-
Reframing “Chronicity” with “Urgency” in Chronic Kidney Disease Management Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-26 Brendon L Neuen, Katherine R Tuttle, George Bakris, Muthiah Vaduganathan
An abstract is unavailable. This article is available as a PDF only.
-
Lessons Learned from HERA: the First Alport Syndrome Therapeutic Clinical Trial Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-21 B. André Weinstock
An abstract is unavailable.
-
Validation of Non-invasive Detection of Hyperkalemia by Artificial Intelligence Enhanced Electrocardiography in High Acuity Settings Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-21 David M. Harmon, Kan Liu, Jennifer Dugan, Jacob C. Jentzer, Zachi I. Attia, Paul A. Friedman, John J. Dillon
e care unit (ICU) cohort (August 2017-February 2018) were identified and analyzed separately. For each group, pairs of laboratory-collected potassium and 12 lead ECGs obtained within four hours of each other were identified. The previously developed AI ECG algorithm was subsequently applied to leads I and II of the 12 lead ECGs to screen for hyperkalemia (potassium > 6.0 mEq/L). Results: The ED cohort
-
Comparison of cardiac autonomic innervation in post-mortem tissue from individuals with kidney failure and preserved kidney function Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-13 Qandeel Soomro, Valeria Mezzano, Navneet Narula, Amy Rapkiewicz, Cynthia Loomis, David M. Charytan
An abstract is unavailable. This article is available as a PDF only.
-
A Six-Year Follow-Up of Bloodstream Infections in Hemodialysis Facilities in the United States, National Healthcare Safety Network, 2020 Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-18 John Keenan, Kira A. Barbre, Philip Dollard, Tamara Hoxworth, Iram Qureshi, Lindsay Dunham, Erin O'Leary, Selom Agbobli Nuwoaty, Suparna Bagchi, Jonathan Edwards, Mary Lu, Andrea Benin, Jeneita Bell
BSI events divided by the predicted number of events based on national aggregate data. Median facility-level standardized infection ratios and 95% confidence intervals (CIs) were stratified by state and US territory. Results During 2020, 7,183 outpatient hemodialysis facilities reported data for 5,235,234 patient months with 15,181 BSI events. Pooled mean rates per 100 person-months were 0.29 (95%
-
How We Treat Dyslipidemia in Prolonged Nephrotic Syndrome Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-12 Claudio Ponticelli, Lorenzo Arnaboldi, Gabriella Moroni, Alessia Fornoni
An abstract is unavailable. This article is available as a PDF only.
-
Mechanisms of antihypertensive effect of chlorthalidone in advanced chronic kidney disease—a causal mediation analysis Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-12 Rajiv Agarwal, Arjun D Sinha, Wanzhu Tu
prespecified analysis, we analyzed the contributions of baseline levels of 24-hour urinary sodium and aldosterone and the changes from baseline to 4 weeks in the multiple mediators reflecting volume status in a causal mediation analysis framework. Baseline levels of these mediators served as covariates. No power calculationfor this analysis was performed. Results: Of the 160 patients randomized, 140
-
Patient and Caregiver Perspective on PRO-Kid Quality of Life Tool Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-12 Lisa Bonebrake, Afton DeLucca
An abstract is unavailable.
-
The Promise and Challenges of Metabolomic Studies in Pediatric CKD Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-12 Sahir Kalim, William E. Smoyer
An abstract is unavailable.
-
Dynamic Individualized Risk Prediction in IgA Nephropathy: Entering the Era of Artificial Intelligence Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-12 Haresh Selvaskandan, Jonathan Barratt
An abstract is unavailable.
-
Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-07 Abhijat Kitchlu, Verônica T. Costa E Silva, Shuchi Anand, Jaya Kala, Ala Abudayyeh, Lesley A. Inker, Mitchell H. Rosner, Sabine Karam, Prakash Gudsoorkar, Shruti Gupta, Sheldon Chen, Nattawat Klomjit, Nelson Leung, Tomaz Milanez, Shveta S. Motwani, Sheikh B. Khalid, Vinay Srinivasan, Rimda Wanchoo, Jan H. Beumer, Geoffrey Liu, Nizar M. Tannir, Ani Orchanian-Cheff, Yimin Geng, Sandra M. Herrmann
nancy and treatment may cause kidney injury and subsequent CKD. To date, there has been lack of guidance to standardize approaches to GFR estimation in the cancer population. In this two-part statement from the American Society of Onco-Nephrology, we present key messages for estimation of GFR in patients with cancer, including the choice of GFR estimating equation, use of race and body surface-area
-
Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies – Perspectives from the ASON Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-07 Abhijat Kitchlu, Verônica T. Costa E Silva, Shuchi Anand, Jaya Kala, Ala Abudayyeh, Lesley A. Inker, Mitchell H. Rosner, Sabine Karam, Prakash Gudsoorkar, Shruti Gupta, Sheldon Chen, Nattawat Klomjit, Nelson Leung, Tomaz Milanez, Shveta S. Motwani, Sheikh B. Khalid, Vinay Srinivasan, Rimda Wanchoo, Jan H. Beumer, Geoffrey Liu, Nizar M. Tannir, Ani Orchanian-Cheff, Yimin Geng, Sandra M. Herrmann
An abstract is unavailable. This article is available as a PDF only.
-
C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First Two Years Post-Transplantation Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-07 Blanca Tarragón, Yonatan Peleg, Geetha Jagannathan, Miroslav Sekulic, Jae-Hyung Chang, David J Cohen, Russell J Crew, Geoffrey K Dube, Hilda E Fernandez, Syed Ali Husain, Sumit Mohan, Heather K Morris, Gerald Appel, Paresh Jadav, Dominick Santoriello, Satoru Kudose, M Barry Stokes, Ibrahim Batal, Andrew Bomback
ent C3G are scarce. We aimed to evaluate C3G recurrence in the allograft, with a focus on histologic presentation and progression. Methods We retrospectively analyzed 18 patients with native kidney failure attributed to C3G (12 C3GN and six DDD) who received a kidney transplant from January 2016 to January 2023. Demographic, genetic, clinical, and histologic data were studied. The Nanostring 770 genes
-
Averaged versus Persistent Reduction in Urine Output to Define Oliguria in Critically Ill Patients, an Observational Study. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-07 Céline Monard, Nathan Bianchi, Tatiana Kelevina, Marco Altarelli, Aziz Chaouch, Antoine Schneider
c dialysis or who declined consent. We extracted hourly UO and, across six hours sliding time-windows, assessed for the presence of oliguria according to the average (mean UO below threshold) and persistent method (all measurements below threshold). For both methods, we compared oliguria’s incidence and association with 90-day mortality, and acute kidney disease (AKD) at hospital discharge. Results:
-
Effects of individualized anemia therapy on hemoglobin stability: a randomized controlled pilot trial in hemodialysis patients. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-11 Doris H. Fuertinger, Lin-Chun Wang, David J. Jörg, Lemuel Rivera Fuentes, Xiaoling Ye, Sabrina Casper, Hanjie Zhang, Ariella Mermelstein, Alhaji Cherif, Kevin Ho, Jochen G. Raimann, Lela Tisdale, Peter Kotanko, Stephan Thijssen
ontrolled trial comparing our anemia therapy assistance software against a standard population-based anemia treatment protocol. We hypothesized that personalized dosing of erythropoiesis stimulating agents (ESA) improves hemoglobin target attainment. Methods: Ninety-six patients undergoing hemodialysis and receiving methoxy polyethylene glycol-epoetin beta were randomized 1:1 to the intervention group
-
Validation of Patient-Reported Outcome measure in pediatric chronic Kidney disease (PRO-Kid) Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-11 Mina Matsuda-Abedini, Michael Zappitelli, Kimberley Widger, Adam Rapoport, Janis M Dionne, Rahul Chanchlani, Susan Samuel, Sara N. Davison, Ke Fan Bei, Veronica Ka Wai Lai, Brenden Dufault, Allison B. Dart
ptoms in children. In the current study, we further assessed the validity and internal consistency of PRO-Kid. Methods: In this multicenter study, children age 8 to 18 years with stages 3-5 CKD, including those on dialysis, were recruited from five pediatric centers. Children completed the 14-item PRO-Kid questionnaire and the validated Pediatric Quality of Life Inventory (PedsQL™ 4.0). We explored
-
DEVELOPING THERAPIES FOR C3G: REPORT OF THE KIDNEY HEALTH INITIATIVE C3G TRIAL ENDPOINTS WORK GROUP Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-03 Carla Nester, Dima A. Decker, Matthias Meier, Shakil Aslam, Andrew S. Bomback, Fernando Caravaca-Fontán, Terence H. Cook, David L. Feldman, Veronique Fremeaux-Bacchi, Daniel P. Gale, Ann Gooch, Sally Johnson, Christoph Licht, Mohit Mathur, Matthew C. Pickering, Manuel Praga, Giuseppe Remuzzi, Viknesh Selvarajah, Richard J. Smith, Hossein Tabriziani, Nicole van de Kar, Yaqin Wang, Edwin Wong, Kirtida
especified trial endpoints as measures of clinical benefit; and (2) opine on efficacy findings they would consider compelling as treatment(s) for C3G in native kidneys. Two subpanels of the C3G Trial Endpoints Work group reviewed the available evidence and uncertainties for the association between the three prespecified endpoints -- (1) proteinuria; (2) estimated glomerular filtration rate (eGFR);
-
A Randomized Controlled Clinical Trial Testing Effects of Lademirsen on Kidney Function Decline in Adults with Alport Syndrome Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-06-03 Daniel P. Gale, Oliver Gross, Fang Wang, Rafael José Esteban de la Rosa, Matthew Hall, John A. Sayer, Gerald Appel, Ali Hariri, Shiguang Liu, Manish Maski, Yuqian Shen, Qi Zhang, Sajida Iqbal, Madhurima Uppara Kowthalam, Julie Lin, Jie Ding, on behalf of the HERA Clinical Trial Group
glomerular filtration rate (eGFR) decline in adults with Alport syndrome at risk of rapid disease progression. Methods: This study was a phase 2 trial of lademirsen, with a randomized, double-blind, placebo-controlled period followed by an open-label period. Adults with Alport syndrome, eGFR >35 to <90 mL/min/1.73 m2, and evidence of rapidly progressive kidney dysfunction were randomized 2:1 to lademirsen
-
Lower Dosage Acute Peritoneal Dialysis versus Acute Intermittent Hemodialysis in Acute Kidney Injury: A Randomized Controlled Trial Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-29 Watanyu Parapiboon, Sajja Tatiyanupanwong, Kamol Khositrangsikun, Thanawat Phulkerd, Piyanut Kaewdoungtien, Watthikorn Pichitporn, Nuttha Lumlertgul, Sadudee Peerapornratana, Fangyue Chen, Nattachai Srisawat
ed controlled trial compared the outcomes between acute lower dosage PD (18-24 liters per day) and Intermittent HD (three times per week) from May 2018 to January 2021 in patients with AKI. The primary outcome was 28-day mortality rate. Secondary outcomes included 28-day dialysis-free survival and kidney recovery, metabolic profile, and procedure-related complications. Non-inferiority of PD to HD would
-
DERIVATION AND VALIDATION OF A MACHINE LEARNING MODEL FOR THE PREVENTION OF UNPLANNED DIALYSIS Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-24 Martin M. Klamrowski, Ran Klein, Christopher McCudden, James R. Green, Babak Rashidi, Christine A. White, Matthew J. Oliver, Amber O. Molnar, Cedric Edwards, Tim Ramsay, Ayub Akbari, Gregory L. Hundemer
D patients who are at high risk for developing kidney failure over short time frames (6-12 months) may help reduce the rates of unplanned dialysis and improve the quality of transitions from CKD to kidney failure. Methods: We performed a retrospective study employing machine learning random forest algorithms incorporating routinely collected age and sex data along with time-varying trends in laboratory
-
Vascular Access Considerations in Home Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-21 Ryan J. Chan, Christopher T. Chan
he establishment and maintenance of a functioning vascular access that serves as a patient’s lifeline while on therapy. While the selection of a vascular access type is influenced by individual patient circumstances, the arteriovenous fistula is generally the preferred access method. Training patients to utilize their dialysis access requires attention to safety, risk management, and monitoring for
-
Prescribing Peritoneal Dialysis in the United States Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-17 Matthew B. Rivara, Rajnish Mehrotra
An abstract is unavailable.
-
Antivirals in Herpes Zoster and AKI: Old Foes, New Insights Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-17 Yuenting Diana Kwong, Raymond K. Hsu
An abstract is unavailable.
-
Benefit of Renin Angiotensin Aldosterone Blockade in Kidney Transplant Recipients: Is the Verdict in or Still to Be Answered? Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-17 Deirdre Sawinski, Amy K. Mottl
An abstract is unavailable.
-
Development and Validation of KRT Knowledge Instrument Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-15 Ashutosh M. Shukla, Brian Visconti, Kailyn Pearce, Tatiana Orozco, Jennifer Hale-Gallardo, Shobha Subhash, I. Magaly Freytes, Huanguang Jia, Sergio Romero, Yi Guo
ts with CKD.Our results show that KRT awareness is different and significantly lower than CKD awareness among patients with advanced CKD. Background Awareness of KRTs is associated with greater home dialysis use. However, validated instruments evaluating patient knowledge and awareness of various KRTs are currently lacking and are critical for informed decision making. Methods We developed a 24-item
-
Acute Kidney Injury, Systemic Inflammation and Long-term Cognitive Function: ASSESS-AKI Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-10 Pavan K. Bhatraju, Leila R. Zelnick, Ian B. Stanaway, T. Alp Ikizler, Steven Menez, Vernon M. Chinchilli, Steve G. Coca, James S. Kaufman, Paul L. Kimmel, Chirag R. Parikh, Alan S. Go, Edward D. Siew, Mark M. Wurfel., Jonathan Himmelfarb
in part, by persistent systemic inflammation. Methods: ASSESS-AKI enrolled patients surviving three months after hospitalization with and without AKI matched based on demographics, comorbidities, and baseline kidney function. A subset underwent cognitive testing using the modified mini-mental status examination (3MS) at 3, 12, and 36 months. We examined the association of AKI with 3MS scores using
-
Development and external validation of a multidimensional deep learning model to dynamically predict kidney outcomes in IgA nephropathy Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-10 Tingyu Chen, Tiange Chen, Wenjie Xu, Shaoshan Liang, Feng Xu, Dandan Liang, Xiang Li, Caihong Zeng, Guotong Xie, Zhihong Liu
. This study aimed at establishing a multivariable dynamic deep learning model using comprehensive longitudinal data for the prediction of kidney outcomes in IgA nephropathy. Methods In this retrospective cohort study of 2,056 IgA nephropathy patients at 18 kidney centers, a total of 28,317 data points were collected by the sliding window method. Among them, 15,462 windows in a single center were randomly
-
A National Survey of Pregnancy and Parenthood Among Nephrology Trainees: A Focus on Nephrology Fellowship Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-10 Angelina Dixon, Nisha Bansal, Susanne B. Nicholas, Anna Ostrow, Jessica Kendrick
ildcare due to nontraditional work hours with extended or unpredictable shifts. Here, we examine awareness of current policies in United States (US) nephrology fellowship programs regarding parental leave, pregnancy/breastfeeding accommodations, and fellows’ perspectives on family planning. Methods: An anonymous, on-line survey of US nephrology fellows was undertaken from June 9 to August, 24, 2023
-
Unexplained Metabolic Alkalosis in an Athlete: Don’t Sweat It Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-10 Roger Rodby, William Whittier
An abstract is unavailable. This article is available as a PDF only.
-
Association of Preterm Birth with Adverse Glomerular Disease Outcomes in Children and Adults Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-10 Jaya Isaac, Jonathan Troost, Yujie Wang, Kelly Garrity, Frederick Kaskel, Rasheed Gbadegesin, Kimberly Reidy
glomerular disease are unknown. Methods: We performed a cross-sectional and longitudinal analysis of participants in the Cure Glomerulonephropathy (CureGN) cohort. Preterm (<37 weeks’ gestation) was compared to term (≥37 weeks’ gestation). A survival analysis and adjusted Cox proportional hazards model were used to examine a composite outcome of 40% decline in estimated glomerular filtration rate (eGFR)
-
A Quality Systems Perspective on Sensitization and Kidney Allocation System Changes Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-13 Laurel Damashek
An abstract is unavailable.
-
Kidney Transplant of the Undocumented Immigrant: A Proposal Whose Benefits Outweigh the Status Quo Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-06 George N. Coritsidis, Adam Block, Isaac Pak, Rajkumar S. Pammal
An abstract is unavailable. This article is available as a PDF only.
-
Rates of Heart Failure with Preserved Ejection Fraction in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-06 Khalid Namoos, Cheng-Wei Huang, In-Lu Amy Liu, Janet S. Lee, David K. Yi, John J. Sim
An abstract is unavailable. This article is available as a PDF only.
-
Longitudinal plasma metabolome patterns and relation to kidney function and proteinuria in pediatric chronic kidney disease Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-06 Arthur M. Lee, Yunwen Xu, Jian Hu, Rui Xiao, Stephen R. Hooper, Erum A. Hartung, Josef Coresh, Eugene P. Rhee, Ramachandran S. Vasan, Paul L. Kimmel, Bradley A. Warady, Susan L. Furth, Michelle R. Denburg, on behalf of the CKD Biomarkers Consortium*
is a limited number of studies of longitudinal metabolomics, and virtually none in pediatric CKD. Methods The Chronic Kidney Disease in Children (CKiD) study is a multi-institutional, prospective cohort that enrolled children aged six-months to 16-years with estimated glomerular filtration rate (eGFR) 30-90ml/min/1.73m2. Untargeted metabolomics profiling was performed on plasma samples from the baseline
-
Genomic Testing in Patients with Kidney Failure of an Unknown Cause: a National Australian Study Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-05-03 Amali C. Mallawaarachchi, Lindsay Fowles, Louise Wardrop, Alasdair Wood, Rosie O’Shea, Erik Biros, Trudie Harris, Stephen I Alexander, Simon Bodek, Neil Boudville, Jo Burke, Leslie Burnett, Sarah Casauria, Steve Chadban, Aron Chakera, Sam Crafter, Pei Dai, Paul De Fazio, Randall Faull, Andrew Honda, Vanessa Huntley, Sadia Jahan, Kushani Jayasinghe, Matthew Jose, Anna Leaver, Mandi MacShane, Evanthia
rs of etiology. We aimed to determine the diagnostic utility of whole-genome sequencing (WGS) with analysis of a broad kidney gene panel in patients with kidney failure of unknown cause. Methods We prospectively recruited 100 participants who reached CKD stage 5 at 50 years of age and had an unknown cause of kidney failure after standard investigation. Clinically-accredited WGS was performed in this
-
Outpatient Nephrology Follow-Up after Community-Acquired Acute Kidney Injury among United States Veterans Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-26 Clarissa J. Diamantidis, Lindsay Zepel, Matthew L. Maciejewski, M. Alan Brookhart, C. Barrett Bowling, Virginia Wang
An abstract is unavailable. This article is available as a PDF only.
-
Utility of Blood Biomarkers to Predict Marrow Iron Stores in Children Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-30 Shilpa Sharma, Renata C. Pereira, Elizabeta Nemeth, Mark R. Hanudel, Joachim H. Ix, Isidro B. Salusky, Tomas Ganz
d standard) in this population with kidney failure who underwent bone biopsies. Methods: This cross-sectional study enrolled 71 clinically stable children and young adults receiving dialysis who underwent bone biopsy for chronic kidney disease-mineral bone disorder between 2007 through 2011. Bone biopsies were stained with Perls’ Prussian blue and independently interpreted by a pathologist blinded
-
Kinetics of β-2-Microglobulin with Hemodiafiltration and High-Flux Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-23 Richard A. Ward, John T. Daugirdas
for β-2-microglobulin removal and generation was used to explore the impact of adding hemodiafiltration on predialysis and time-averaged serum values. Methods The model was tested on data from the HEMO study and on a sample of patients undergoing high-flux hemodialysis. The impact of hemodiafiltration on β-2-microglobulin levels was evaluated by modeling four randomized studies of hemodiafiltration
-
Time is Money: Protected Time for Fellow Education Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-17 Alice M. Sheridan
An abstract is unavailable.
-
The Clinical Study of Kidney Stone Disease and the Value of Specificity Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-17 Alan C. Pao, Calyani Ganesan
An abstract is unavailable.
-
Did the SCORED Trial Get Extra Points for Kidney Outcomes? If So, It Is Not Obvious Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-17 Nupur Mistry, George L. Bakris
An abstract is unavailable.
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-16 Robert A. Fletcher, William G. Herrington, Rajiv Agarwal, Kaitlin J. Mayne, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Natalie Staplin, David C. Wheeler, Glenn M. Chertow, Hiddo J.L. Heerspink, Brendon L. Neuen
Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).
-
Association of Inflammatory Bowel Disease with Incident IgA Nephropathy Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-04-11 Takashin Nakayama, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Norihiko Takeda, Akira Fukui, Takashi Yokoo, Hideo Yasunaga, Masaomi Nangaku, Kaori Hayashi
between inflammatory bowel disease and the incidence of IgA nephropathy. In this study, we assessed whether inflammatory bowel disease was associated with a higher risk of developing IgA nephropathy using a large-scale epidemiologic cohort. Methods We retrospectively analyzed 4,311,393 adults enrolled in the JMDC Claims Database (previously known as the Japan Medical Data Center database), a nationwide
-
Nonlupus Full House Nephropathy: A Systematic Review Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-26 Martina Uzzo, Andreas Kronbichler, Federico Alberici, Ingeborg Bajema
h comparable outcomes.The identification of three pathogenetic categories provides further clues for a shared clinical and diagnostic approach to the disease. Background The presence of a full house pattern at immunofluorescence on kidney biopsy in a patient without clinical and laboratory features of systemic lupus erythematosus (SLE) has led to the descriptive term nonlupus full house nephropathy
-
Associations between Different Antivirals and Hospital-Acquired Acute Kidney Injury in Adults with Herpes Zoster Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-26 Ruqi Xu, Qi Gao, Yuping Zhang, Yuxin Lin, Yanqin Li, Licong Su, Shiyu Zhou, Yue Cao, Peiyan Gao, Pingping Li, Fan Luo, Ruixuan Chen, Xiaodong Zhang, Sheng Nie, Xin Xu, the CRDS study Investigators
n of use of different antivirals with hospital-acquired AKI among Chinese adults with herpes zoster. Methods This study selected 3273 adult patients who received antiviral therapy for herpes zoster during hospitalization from the China Renal Data System. We identified and staged AKI using patient-level serum creatinine data according to the Kidney Disease Improving Global Outcomes criteria. We compared
-
Calibration of Priority Points for Sensitization Status of Kidney Transplant Candidates in the United States Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-21 Jesse. D. Schold, Anat R. Tambur, Sumit Mohan, Bruce Kaplan
ity points assigned to candidates associated with sensitization have led to inequities in access to deceased donor transplantation. Background A primary change to the national organ allocation system in 2014 for deceased donor kidney offers was to weight candidate priority on the basis of sensitization (i.e., calculated panel reactive antibody percentage [cPRA%]) using a sliding scale. Increased priority
-
Clinical Outcomes after a Kidney Stone Event in Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-14 Ganesan, Calyani, Liu, Sai, Montez-Rath, Maria, Leppert, John T., Pao, Alan C.
No abstract available
-
How We Treat Primary Hyperoxaluria Type 1 Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-18 Matthew C. Breeggemann, Peter C. Harris, John C. Lieske, Gregory E. Tasian, Kyle D. Wood
An abstract is unavailable.
-
How We Treat Primary Hyperoxaluria Type 1 Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-18 Breeggemann, Matthew C., Harris, Peter C., Lieske, John C., Tasian, Gregory E., Wood, Kyle D.
No abstract available
-
The Future of the US Nephrology Workforce following the End of Affirmative Action Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-07 Deidra C. Crews
An abstract is unavailable.
-
KRT in Patients with AKI and Cirrhosis Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-05 Sapna V. Shah, Mitra K. Nadim
An abstract is unavailable.
-
Cover Image Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-03-01 Bakis, Hugo
No abstract available
-
-
Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-02-29 Xiaofan Hu, Jing Xu, Wei Wang, Lili Liu, Yuanmeng Jing, Chenni Gao, Xialian Yu, Yi Li, Li Lin, Jun Tong, Qinjie Weng, Xiaoxia Pan, Wen Zhang, Hong Ren, Guisen Li, Krzysztof Kiryluk, Nan Chen, Jingyuan Xie
of 519 biopsy-proven PLA2R-associated primary membranous nephropathy patients with baseline eGFR ≥25 ml/min per 1.73 m2. The combined risk score was calculated by combining the genetic risk score with PLA2R ELISA antibody titers. The primary end point was kidney disease progression defined as a 50% reduction in eGFR or kidney failure. Cox proportional hazard regression analysis and C-statistics were
-
Combined Serologic and Genetic Risk Score and Prognostication of PLA2R-Associated Membranous Nephropathy Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-02-29 Hu, Xiaofan, Xu, Jing, Wang, Wei, Liu, Lili, Jing, Yuanmeng, Gao, Chenni, Yu, Xialian, Li, Yi, Lin, Li, Tong, Jun, Weng, Qinjie, Pan, Xiaoxia, Zhang, Wen, Ren, Hong, Li, Guisen, Kiryluk, Krzysztof, Chen, Nan, Xie, Jingyuan
Introduction: The aim of this study was to test whether a combined risk score based on genetic risk and serology can improve the prediction of kidney failure in PLA2R-associated primary membranous nephropathy. Methods: We performed a retrospective analysis of 519 biopsy-proven PLA2R-associated primary membranous nephropathy patients with baseline eGFR ≥ 25ml/min/1.73m2. The combined risk score was